Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2280]

Highlights of the EurocanPlatform Project

Highlights of the EurocanPlatform Project ( )

Cancer Core Europe: one year on (full version)

Prof Alexander Eggermont - Gustave Roussy, Villejuf, France

Cancer Core Europe: one year on (full version) ( Prof Alexander Eggermont - Gustave Roussy, Villejuf, France )

Treating elderly patients at the molecular level

Dr Christophe Massard - Institut Gustave Roussy, Paris, France

Treating elderly patients at the molecular level ( Dr Christophe Massard - Institut Gustave Roussy, Paris, France )

Four molecular subtypes identified in pancreatic cancer

Dr David Chang - University of Glasgow, Glasgow, UK

Four molecular subtypes identified in pancreatic cancer ( Dr David Chang - University of Glasgow, Glasgow, UK )

NCRI 2015 highlights

Prof Charles Swanton - Cancer Research UK's London Research Institute, London...

NCRI 2015 highlights ( Prof Charles Swanton - Cancer Research UK's London Research Institute, London, UK )

Prognostic value of BRAFV600 mutations in stage 3 cutaneous melanoma patients

Prof Philippe Saiag - University of Versailles, Versailles, France

Prognostic value of BRAFV600 mutations in stage 3 cutaneous melanoma patients ( Prof Philippe Saiag - University of Versailles, Versailles, France )

Anti-PD1 or tyrosine kinase inhibitors?

Dr Mark Middleton - University of Oxford, Oxford, UK

Anti-PD1 or tyrosine kinase inhibitors? ( Dr Mark Middleton - University of Oxford, Oxford, UK )

Disruptive technologies in cancer

Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia

Disruptive technologies in cancer ( Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia )

Latest from the CoBRIM study

Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia

Latest from the CoBRIM study ( Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia )

Anti-PD-1 or anti-CTLA-4 in first line therapy?

Prof Claus Garbe - University of Tübingen, Tübingen, Germany

Anti-PD-1 or anti-CTLA-4 in first line therapy? ( Prof Claus Garbe - University of Tübingen, Tübingen, Germany )

Long response and long responders in melanoma immunology

Prof Georgina Long - University of Sydney, Sydney, Australia

Long response and long responders in melanoma immunology ( Prof Georgina Long - University of Sydney, Sydney, Australia )

Progress in targeted therapy of melanoma

Prof Keith Flaherty - Massachusetts General Hospital, Boston, USA

Progress in targeted therapy of melanoma ( Prof Keith Flaherty - Massachusetts General Hospital, Boston, USA )

More from ecancer